- Home
- BRT vs ACRS Comparison
BRT vs ACRS Comparison
Compare BRT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | ACRS |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 311.0M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRT | ACRS |
|---|---|---|
| Price | $14.49 | $4.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.75 | $10.20 |
| AVG Volume (30 Days) | 21.1K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $1,683,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $1.27 |
| 52 Week High | $16.69 | $5.15 |
Technical Indicators
Market Signals| Indicator | BRT | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 51.00 |
| Support Level | $14.25 | $4.08 |
| Resistance Level | $15.01 | $4.56 |
| Average True Range (ATR) | 0.40 | 0.25 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 56.32 | 29.89 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.